Unknown

Dataset Information

0

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis.


ABSTRACT:

Background

The mesenchymal-epithelial transition factor (MET) receptor is dysregulated in hepatocellular carcinoma (HCC), and tivantinib (ARQ 197) is an oral, selective, MET inhibitor.

Methods

This Phase-1b study assessed tivantinib safety as primary objective in patients with previously treated HCC and Child-Pugh A or B liver cirrhosis. Patients received oral tivantinib 360 mg twice daily until disease progression or unacceptable toxicity.

Results

Among 21 HCC patients, common drug-related adverse events (AEs) were neutropaenia, anaemia, asthenia, leucopaenia, anorexia, diarrhoea, and fatigue. No drug-related worsening of liver function or performance status occurred, but one Child-Pugh B patient experienced drug-related bilirubin increase. Four patients had drug-related serious AEs, including one neutropaenia-related death. Haematologic toxicities were more frequent than in previous tivantinib studies but were manageable with prompt therapy. Best response was stable disease (median, 5.3 months) in 9 of 16 evaluable patients (56%). Median time to progression was 3.3 months.

Conclusion

Tivantinib demonstrated a manageable safety profile and preliminary antitumour activity in patients with HCC and Child-Pugh A or B cirrhosis.

SUBMITTER: Santoro A 

PROVIDER: S-EPMC3553536 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5406425 | biostudies-literature
| S-EPMC3759033 | biostudies-literature
| S-EPMC4372650 | biostudies-literature
| S-EPMC5736844 | biostudies-literature
| S-EPMC5528687 | biostudies-literature
| S-EPMC6095177 | biostudies-literature
| S-EPMC4673154 | biostudies-literature
| S-EPMC8085979 | biostudies-literature
| S-EPMC5071720 | biostudies-literature
| 2147788 | ecrin-mdr-crc